Garufi Giovanna, Carbognin Luisa, Schettini Francesco, Seguí Elia, Di Leone Alba, Franco Antonio, Paris Ida, Scambia Giovanni, Tortora Giampaolo, Fabi Alessandra
Oncologia Medica, Fondazione Policlinico Universitario Agostino Gemelli IRCCS, 00168 Roma, Italy.
Oncologia Medica, Università Cattolica Del Sacro Cuore, 00168 Roma, Italy.
Cancers (Basel). 2022 Aug 23;14(17):4064. doi: 10.3390/cancers14174064.
Triple-negative breast cancer (TNBC) is characterized by the absence of hormone receptor and HER2 expression, and therefore a lack of therapeutic targets. Anthracyclines and taxane-based neoadjuvant chemotherapy have historically been the cornerstone of treatment of early TNBC. However, genomic and transcriptomic analyses have suggested that TNBCs include various subtypes, characterized by peculiar genomic drivers and potential therapeutic targets. Therefore, several efforts have been made to expand the therapeutic landscape of early TNBC, leading to the introduction of platinum and immunomodulatory agents into the neoadjuvant setting. This review provides a comprehensive overview of the currently available evidence regarding platinum agents and immune-checkpoint-inhibitors for the neoadjuvant treatment of TNBC, as well as the novel target therapies that are currently being evaluated in this setting. Taking into account the economic issues and the side effects of the expanding therapeutic options, we focus on the potential efficacy biomarkers of the emerging therapies, in order to select the best therapeutic strategy for each specific patient.
三阴性乳腺癌（TNBC）的特征是缺乏激素受体和HER2表达，因此缺乏治疗靶点。蒽环类药物和紫杉烷类新辅助化疗一直是早期TNBC治疗的基石。然而，基因组和转录组分析表明，TNBC包括多种亚型，其特征是具有独特的基因组驱动因素和潜在的治疗靶点。因此，人们已经做出了多项努力来拓展早期TNBC的治疗领域，从而将铂类药物和免疫调节药物引入新辅助治疗中。本综述全面概述了目前关于铂类药物和免疫检查点抑制剂用于TNBC新辅助治疗的现有证据，以及目前正在该治疗背景下进行评估的新型靶向治疗。考虑到不断扩展的治疗选择所带来的经济问题和副作用，我们关注新兴疗法的潜在疗效生物标志物，以便为每个特定患者选择最佳治疗策略。
